Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • Myeloma
      • Highlights from BCD
      • COVID-19 & Cancer Resource Center
  • For Authors
    • Information for Authors
    • Author Services
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Blood Cancer Discovery

Blood Cancer Discovery

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • Myeloma
      • Highlights from BCD
      • COVID-19 & Cancer Resource Center
  • For Authors
    • Information for Authors
    • Author Services
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

The AACR remains fully committed to supporting publishing operations throughout this challenging time, while still remaining flexible and supportive of the author, reviewer, and editor communities that we serve. If you have any questions or concerns, please reach out to a member of the AACR publishing staff.
Please visit the COVID-19 & Cancer Resource Center where COVID-related content is freely available.

 

Follow @BCD_AACR on Twitter!

  • Current Cover of Blood Cancer Discovery
    Read the March issue!
    In this issue, the team of Jha, Maciejewski, and colleagues shows that minimal TET activity is essential for neoplastic cell survival and underlies synthetic lethality of TET and IDH mutations.
  • Science in Society
    Science in Society
    Read: Recommendations on Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step toward Achieving Equity in Healthcare, Kenneth C. Anderson et al.
  • Spotlight
    Spotlight
    Read: Understanding FLT3 Inhibitor Resistance to Rationalize Combinatorial AML Therapies, Amit Verma et al.
  • Spotlight
    Spotlight
    Read: MYC and TFEB Control DNA Methylation and Differentiation in AML, Robert N. Eisenman et al.
  • 1
  • 2
  • 3
  • 4

From the Current Issue

  • Research Articles | Free Article
    A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient Cells in Myeloid Neoplasms
    Yihong Guan, Anand D. Tiwari, James G. Phillips, Metis Hasipek, Dale R. Grabowski, Simona Pagliuca, Priyanka Gopal, Cassandra M. Kerr, Vera Adema, Tomas Radivoyevitch, Yvonne Parker, Daniel J. Lindner, Manja Meggendorfer, Mohamed Abazeed, Mikkeal A. Sekeres, Omar Y. Mian, Torsten Haferlach, Jaroslaw P. Maciejewski and Babal K. Jha
    Blood Cancer Discov March 1 2021 2 (2) 146-161; DOI:10.1158/2643-3230.BCD-20-0173

    2HG accumulation from IDH1/2 mutation induces synthetic lethality in TET2-mutant cells by reducing TET activity below essentially required. A new TET inhibitor mimics 2HG and selectively restricts clonal evolution of TET2-mutant cells in vitro and in vivo.

  • Research Brief | Free Article
    Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors
    Ahmad S. Alotaibi, Musa Yilmaz, Rashmi Kanagal-Shamanna, Sanam Loghavi, Tapan M. Kadia, Courtney D. DiNardo, Gautam Borthakur, Marina Konopleva, Sherry A. Pierce, Sa A. Wang, Guilin Tang, Veronica Guerra, Bachar Samra, Naveen Pemmaraju, Elias Jabbour, Nicholas J. Short, Ghayas C. Issa, Maro Ohanian, Guillermo Garcia-Manero, Kapil N. Bhalla, Keyur P. Patel, Koichi Takahashi, Michael Andreeff, Jorge E. Cortes, Hagop M. Kantarjian, Farhad Ravandi and Naval Daver
    Blood Cancer Discov March 1 2021 2 (2) 125-134; DOI:10.1158/2643-3230.BCD-20-0143

    Genetic patterns underlying resistance to Flt3-targeted therapies in AML reveal distinct drivers associated with relapse on type 1 versus type 2 inhibitors and link mutation emergence with clinical outcomes.

  • Research Articles | Free Article
    TFEB Links MYC Signaling to Epigenetic Control of Myeloid Differentiation and Acute Myeloid Leukemia
    Seongseok Yun, Nicole D. Vincelette, Xiaoqing Yu, Gregory W. Watson, Mario R. Fernandez, Chunying Yang, Taro Hitosugi, Chia-Ho Cheng, Audrey R. Freischel, Ling Zhang, Weimin Li, Hsinan Hou, Franz X. Schaub, Alexis R. Vedder, Ling Cen, Kathy L. McGraw, Jungwon Moon, Daniel J. Murphy, Andrea Ballabio, Scott H. Kaufmann, Anders E. Berglund and John L. Cleveland
    Blood Cancer Discov March 1 2021 2 (2) 162-185; DOI:10.1158/2643-3230.BCD-20-0029

    MYC directly inhibits expression of TFEB, which serves as a tumor suppressor in AML via promoting myeloid differentiation and cell death. TFEB induces IDH1/2 expression to establish myeloid epigenetic programs, and it is a druggable target in AML.

  • Research Brief | Free Article
    Ectopic Humanized Mesenchymal Niche in Mice Enables Robust Engraftment of Myelodysplastic Stem Cells
    Syed A. Mian, Ander Abarrategi, Kar Lok Kong, Kevin Rouault-Pierre, Henry Wood, Caroline A. Oedekoven, Alexander E. Smith, Antoniana Batsivari, Linda Ariza-McNaughton, Peter Johnson, Thomas Snoeks, Ghulam J. Mufti and Dominique Bonnet
    Blood Cancer Discov March 1 2021 2 (2) 135-145; DOI:10.1158/2643-3230.BCD-20-0161

    Human bone marrow stromal niche engineering in mice supports long-term engraftment of primary patient MDS cells with preserved disease characteristics.


OnlineFirst Articles

  • Non-oncogene Addiction to SIRT5 in Acute Myeloid Leukemia
    Meng Li, Ari M. Melnick
  • A Critical Role for SIRT5 in AML Metabolism
    Dongqing Yan, et al.
  • Clonal Hematopoiesis in Classic Hodgkin Lymphoma
    Alessandra Venanzi, et al.
  • ROBO1 supports myeloma dissemination and proliferation
    Giada Bianchi, et al.
Load more

Trending - Altmetric

No Altmetric data available.
Advertisement
Back to top
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Blood Cancer Discovery

  • About the Journal
  • Editors
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Blood Cancer Discovery
eISSN: 2643-3249
ISSN: 2643-3230

Advertisement